

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJMN1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent
number searching
NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing
enhanced
NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
Applications
NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of
pre-registered REACH substances
NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 9 NOV 26 MARPAT enhanced with FSORT command
NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts
availability of new fully-indexed citations
NEWS 11 NOV 26 CHEMSAFE now available on STN Easy
NEWS 12 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 13 DEC 01 ChemPort single article sales feature unavailable
NEWS 14 DEC 12 GBFULL now offers single source for full-text
coverage of complete UK patent families

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:10:18 ON 13 DEC 2008

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:10:38 ON 13 DEC 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 DEC 2008 HIGHEST RN 1083471-57-1

DICTIONARY FILE UPDATES: 12 DEC 2008 HIGHEST RN 1083471-57-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10581340\electd species.str



chain nodes :

1 2 3 4 5 7 8 14 15 16

ring nodes :

6 9 10 11 12 13

chain bonds :

1-2 2-3 2-7 3-4 3-8 4-5 5-6 5-14 14-15 15-16

ring bonds :

6-9 6-13 9-10 10-11 11-12 12-13

exact/norm bonds :

2-7 3-4 3-8 4-5 14-15 15-16

exact bonds :

1-2 2-3 5-6 5-14

normalized bonds :

6-9 6-13 9-10 10-11 11-12 12-13

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:CLASS 8:CLASS 9:Atom


10:Atom 11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 15:10:58 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 474 TO ITERATE

100.0% PROCESSED 474 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L2 1 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 15:11:02 ON 13 DEC 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Dec 2008 VOL 149 ISS 25
FILE LAST UPDATED: 12 Dec 2008 (20081212/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 12

L3 1 L2

=> d ibib abs hitstr

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:588522 CAPLUS
 DOCUMENT NUMBER: 143:120530
 TITLE: Nitric oxide-releasing pyruvate compounds, compositions and methods for treating cardiovascular and other diseases
 INVENTOR(S): Garvey, David S.; Fang, Xinqin; Subhash, Khanapure P.;
 Ramani, Ranatunga R.; Shioh-Jyi, Wey
 PATENT ASSIGNEE(S): NitroMed, Inc., USA
 SOURCE: PCT Int. Appl., 82 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060603	A2	20050707	WO 2004-US41069	20041210
WO 2005060603	A3	20051201		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SE, TE, UG, ZM, ZW, AM, AS, BY, KG, KG, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004305016	A1	20050707	AU 2004-305016	20041210
CA 2549412	A1	20050707	CA 2004-2549412	20041210
EP 1692107	A2	20060823	EP 2004-813393	20041210
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, HU, IE, IS, IT, LT, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
US 20080287407	A1	20081120	US 2006-581340	20060602
PRIORITY APPLN. INFO.:			US 2003-528184P	P 20031210
			WO 2004-US41069	W 20041210

OTHER SOURCE(S): MARPAT 143:120530
 AB The invention describes novel pyruvate compds. comprising at least one nitric oxide-releasing group and pharmaceutically acceptable salts thereof, and kits comprising at least one of these pyruvate compds., and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The therapeutic agent is, e.g., an aldosterone antagonist, α -adrenoceptor antagonist, an angiotensin II antagonist, an ACE inhibitor, an antidiabetic, an antihyperlipidemic agent, an antioxidant, an antithrombotic, a vasodilator, a β -adrenoceptor antagonist, a calcium channel blocker, a digitalis, a diuretic, etc. The invention also provides methods for treating cardiovascular diseases, renovascular diseases, diabetes, diseases resulting from oxidative stress,

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 endothelial dysfunctions, diseases caused by endothelial dysfunctions, cirrhosis, pre-eclampsia, osteoporosis, nephropathy, reperfusion injury following ischemia, and/or preserving tissues, organs, organ parts and/or limbs using these compns. The nitric oxide releasing group is preferably a nitro group, a nitroso group, and/or a heterocyclic nitric oxide donor group. The heterocyclic nitric oxide donor group is preferably a furoxan, a sydnonimine, an oxatriazole-5-one and/or an oxatriazole-5-imine. Thus, a mixt. of nitrooxy-4-piperidyl nitrate (1.045 g, 5 mmol) and pyruvic acid (440 mg, 5 mmol) in dichloromethane was treated with triethylamine (0.7 mL). To this soln. was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDAC) (960 mg, 5 mmol) followed by dimethylaminopyridine (DMAP, 610 mg, 5 mmol). The resulting soln. was then stirred under nitrogen atm. at room temp. overnight. The reaction mixt. was dild. with dichloromethane and washed with water, brine, dried over sodium sulfate, filtered, and the solvent was evapd. at reduced pressure. The product was purified by column chromatog. to give 1-[4-(nitrooxy)piperidyl]propane-1,2-dione (470 mg, 44% yield) as a colorless thick oil.
 IT 857464-14-3P
 RI: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of nitric oxide-releasing pyruvate compds. and compns. for treating cardiovascular and other diseases)
 RN 857464-14-3 CAPLUS
 CN Propanamide, N-[(1S)-2-(nitrooxy)-1-phenylethyl]-2-oxo- (CA INDEX NAME)
 Absolute stereochemistry.

